

NeuroSearch A/S
Pederstrupvej 93
DK - 2750 Ballerup
Denmark
Telephone: +45 4460 8000
Telefax: +45 4460 8080
ns@neurosearch.dk
www.neurosearch.com
CVR No: DK-12 54 61 06

Announcement

Report on Extraordinary General Meeting held in NeuroSearch A/S

Pursuant to announcement, the Extraordinary General Meeting of NeuroSearch A/S was held today Wednesday, 20 May 2009.

The suggested amendments to the Articles of Association were adopted by the General Meeting: Article 5 following which the Board of Directors is authorised to increase the company's share capital in one or more issues of up to a total nominal value of DKK 60,000,000 (3.000.000 shares of DKK 20 each) until 1 April 2014, article 5a following which the Board of Directors is authorised to issue warrants by one or more issues for up to a total nominal value of DKK 10,000,000 (5,000,000 shares of DKK 20 each) to some or all of the company's or the company's subsidiaries' employees, Board members and Executive Management on terms laid down by the Board of Directors for the period ending on 31 December 2010 and article 5k following which the Board of Directors is authorised to raise loan against issue of convertible bonds in one or more issues until 31.12.2010 by up to DKK 162,000,000. Furthermore, it was decided to amend article 8 of the Articles of Association to state I-NVESTOR DANMARK A/S, Kongevejen 418, DK-2840 Holte as the company's registrar of shareholders.

Flemming Pedersen
CEO

Contact persons:

Flemming Pedersen, CEO, telephone: +45 2148 0118
Hanne Leth Hillman, Vice President, Director of Investor & Capital Market Relations, telephone: +45 4017 5103

NeuroSearch - Company profile

NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on Nasdaq OMX Copenhagen. The company's core business covers the development of novel drugs, based on a broad and well-established drug discovery platform focusing on ion channels and central nervous system (CNS) disorders. A substantial share of the activities is partner financed through strategic alliances with Eli Lilly and Company and GlaxoSmithKline (GSK) and a license collaboration with Abbott. The drug pipeline comprises seven clinical (Phase I-III) development programmes: ACR16 for Huntington's disease (Phase III), tesofensine for obesity (Phase III ready), ABT-894 for ADHD (Phase II) in partnership with Abbott, ACR325 to treat dyskinesias in Parkinson's disease (Phase II ready), ACR343 for schizophrenia (Phase I), ABT-560 for the treatment of various CNS disorders (Phase I) in collaboration with Abbott, and NSD-788 for anxiety/depression (Phase I). In addition, NeuroSearch has a broad portfolio of preclinical drug candidates and holds equity interests in several biotech companies.

